
ImmunityBio Seeks Urgent FDA Meeting After Sudden sBLA Reversal
ImmunityBio Requests Urgent FDA Meeting After Refusal to File sBLA for ANKTIVA in NMIBC Papillary Disease, Citing Sudden Reversal from January Guidance ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company focused on developing therapies for difficult-to-treat cancers and infectious diseases,…











